Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Differential expression of p42.3 in low- and high-grade gliomas

Authors: Weiqing Wan, Xiaoqing Xu, Guijun Jia, Wenmei Li, Junmei Wang, Tong Ren, Zhen Wu, Junting Zhang, Liwei Zhang, Youyong Lu

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Malignant gliomas are the most common form of primary malignant brain tumor. It has recently been suggested that genetic changes are involved in the progression of malignant gliomas. In previous studies, a novel gene, p42.3, was characterized as a tumor-specific gene that encodes a mitosis phase–dependent expression protein which is expressed in gastric cancer, but not in matched normal tissues.

Methods

In a series of 200 human brain gliomas and 13 normal tissues, we performed RT-PCR and mRNA in situ hybridization for analysis of p42.3 gene expression in gliomas, including astrocytoma (grade 2), oligoastrocytomas (grade 2), anaplastic oligoastrocytomas (grade 3), glioblastomas (grade 4) and normal tissues. Also, the mRNA expression was detected in gliomas by in situ hybridization. After producing polyclonal antibody to p42.3, we further tested p42.3 protein expression in astrocytomas and glioblastomas by immunohistochemistry and Western blot analysis.

Results

Our results demonstrated that overexpression of the p42.3 gene is detected in gliomas, but not in normal brain tissues. Importantly, p42.3 mRNA expression is correlated with the pathological features of gliomas. In addition, p42.3 protein is expressed in both the cytoplasm and the nucleus in astrocytomas, whereas this protein appeared in the cytoplasm in glioblastomas.

Conclusions

These results indicate that p42.3 might be involved in carcinogenesis as a potential molecular marker for malignant gliomas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shiras A, Bhosale A, Shepal V, Shukla R, Baburao VS, Prabhakara K, Shastry P: A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers. Neoplasia. 2003, 5: 520-532. 10.1016/S1476-5586(03)80036-2.PubMedCentralCrossRefPubMed Shiras A, Bhosale A, Shepal V, Shukla R, Baburao VS, Prabhakara K, Shastry P: A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers. Neoplasia. 2003, 5: 520-532. 10.1016/S1476-5586(03)80036-2.PubMedCentralCrossRefPubMed
2.
go back to reference Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002, 61: 215-229.PubMed Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002, 61: 215-229.PubMed
3.
go back to reference Belda-Iniesta C, de Castro CJ, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M: Molecular biology of malignant gliomas. Clin Transl Oncol. 2006, 8: 635-641. 10.1007/s12094-006-0033-9.CrossRefPubMed Belda-Iniesta C, de Castro CJ, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M: Molecular biology of malignant gliomas. Clin Transl Oncol. 2006, 8: 635-641. 10.1007/s12094-006-0033-9.CrossRefPubMed
4.
go back to reference Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001, 61: 6674-6678.PubMed Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001, 61: 6674-6678.PubMed
5.
go back to reference Louis DN, Pomeroy SL, Cairncross JG: Fuscous on central nervous system neoplasia. Cancer Cell. 2002, 1: 125-128. 10.1016/S1535-6108(02)00040-5.CrossRefPubMed Louis DN, Pomeroy SL, Cairncross JG: Fuscous on central nervous system neoplasia. Cancer Cell. 2002, 1: 125-128. 10.1016/S1535-6108(02)00040-5.CrossRefPubMed
6.
go back to reference Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1999, 1: 44-51.PubMedCentralPubMed Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1999, 1: 44-51.PubMedCentralPubMed
7.
go back to reference Gilbertson RJ: High-grade glioma: Can we teach an old dogma new tricks?. Cancer Cell. 2006, 9: 147-148. 10.1016/j.ccr.2006.02.024.CrossRefPubMed Gilbertson RJ: High-grade glioma: Can we teach an old dogma new tricks?. Cancer Cell. 2006, 9: 147-148. 10.1016/j.ccr.2006.02.024.CrossRefPubMed
8.
go back to reference Ohgaki H: Genetic pathways to glioblastomas. Neuropathology. 2005, 25: 1-7. 10.1111/j.1440-1789.2004.00600.x.CrossRefPubMed Ohgaki H: Genetic pathways to glioblastomas. Neuropathology. 2005, 25: 1-7. 10.1111/j.1440-1789.2004.00600.x.CrossRefPubMed
9.
go back to reference Rich JN, Bigner DD: Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004, 3: 430-446. 10.1038/nrd1380.CrossRefPubMed Rich JN, Bigner DD: Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004, 3: 430-446. 10.1038/nrd1380.CrossRefPubMed
10.
go back to reference Hu B, Jarzynka MJ, Guo P, Imanishi Y, Schlaepfer DD, Cheng SY: Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the αvβ1 integrin and focal adhesion kinase signaling pathway. Cancer Res. 2006, 66: 775-783. 10.1158/0008-5472.CAN-05-1149.PubMedCentralCrossRefPubMed Hu B, Jarzynka MJ, Guo P, Imanishi Y, Schlaepfer DD, Cheng SY: Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the αvβ1 integrin and focal adhesion kinase signaling pathway. Cancer Res. 2006, 66: 775-783. 10.1158/0008-5472.CAN-05-1149.PubMedCentralCrossRefPubMed
11.
go back to reference Xu X, Li W, Fan X, Liang Y, Zhao M, Zhang J, Liang Y, Tong W, Wang J, Yang W, Lu Y: Identification and characterization of a novel p42.3 gene as tumor-specific and mitosis phase-dependent expression in gastric cancer. Oncogene. 2007, 26: 7371-7379. 10.1038/sj.onc.1210538.CrossRefPubMed Xu X, Li W, Fan X, Liang Y, Zhao M, Zhang J, Liang Y, Tong W, Wang J, Yang W, Lu Y: Identification and characterization of a novel p42.3 gene as tumor-specific and mitosis phase-dependent expression in gastric cancer. Oncogene. 2007, 26: 7371-7379. 10.1038/sj.onc.1210538.CrossRefPubMed
12.
go back to reference Murata T, Furushima K, Hirano M, Kiyonari H, Nakamura M, Suda Y, Aizawa S: ang is a novel gene expressed in early neuroectoderm, but its null mutant exhibits no obvious phenotype. Gene Expr Patterns. 2004, 5: 171-178. 10.1016/j.modgep.2004.08.007.CrossRefPubMed Murata T, Furushima K, Hirano M, Kiyonari H, Nakamura M, Suda Y, Aizawa S: ang is a novel gene expressed in early neuroectoderm, but its null mutant exhibits no obvious phenotype. Gene Expr Patterns. 2004, 5: 171-178. 10.1016/j.modgep.2004.08.007.CrossRefPubMed
13.
go back to reference Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002, 359: 1011-1018.CrossRefPubMed Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002, 359: 1011-1018.CrossRefPubMed
14.
go back to reference Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yaşargil MG, Lütolf UM, Kleihues P: Pathways to glioblastoma: a population based study. Cancer Res. 2004, 64: 6892-6899. 10.1158/0008-5472.CAN-04-1337.CrossRefPubMed Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yaşargil MG, Lütolf UM, Kleihues P: Pathways to glioblastoma: a population based study. Cancer Res. 2004, 64: 6892-6899. 10.1158/0008-5472.CAN-04-1337.CrossRefPubMed
15.
go back to reference Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M, Kuratsu J, Saya H, Ushio Y: Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg. 2002, 96: 815-822. 10.3171/jns.2002.96.5.0815.CrossRefPubMed Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M, Kuratsu J, Saya H, Ushio Y: Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg. 2002, 96: 815-822. 10.3171/jns.2002.96.5.0815.CrossRefPubMed
16.
go back to reference Labuhn M, Jones G, Speel EJ, Maier D, Zweifel C, Gratzl O, Van Meir EG, Hegi ME, Merlo A: Quantitative real-time PCR does not show selective targeting of p14 ARF but concomitant inactivation of both p16 INK4A and p14 ARF in 105 human primary gliomas. Oncogene. 2001, 20: 1103-1109. 10.1038/sj.onc.1204197.CrossRefPubMed Labuhn M, Jones G, Speel EJ, Maier D, Zweifel C, Gratzl O, Van Meir EG, Hegi ME, Merlo A: Quantitative real-time PCR does not show selective targeting of p14 ARF but concomitant inactivation of both p16 INK4A and p14 ARF in 105 human primary gliomas. Oncogene. 2001, 20: 1103-1109. 10.1038/sj.onc.1204197.CrossRefPubMed
17.
go back to reference Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6: 217-224. 10.1111/j.1750-3639.1996.tb00848.x.CrossRefPubMed Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6: 217-224. 10.1111/j.1750-3639.1996.tb00848.x.CrossRefPubMed
18.
go back to reference Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene. 1995, 10: 2243-2246.PubMed Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene. 1995, 10: 2243-2246.PubMed
19.
go back to reference Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nordenskjöld M, Larsson C: Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet. 1993, 92: 169-174.CrossRefPubMed Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nordenskjöld M, Larsson C: Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet. 1993, 92: 169-174.CrossRefPubMed
20.
go back to reference Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP: Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Gene Chromosome Canc. 1998, 22: 9-15. 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1.CrossRef Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP: Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Gene Chromosome Canc. 1998, 22: 9-15. 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1.CrossRef
21.
go back to reference Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275: 1943-1947. 10.1126/science.275.5308.1943.CrossRefPubMed Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275: 1943-1947. 10.1126/science.275.5308.1943.CrossRefPubMed
22.
go back to reference Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WK, Steck PA: Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998, 4: 2447-2454.PubMed Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WK, Steck PA: Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998, 4: 2447-2454.PubMed
23.
go back to reference Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001, 93: 1246-1256. 10.1093/jnci/93.16.1246.CrossRefPubMed Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001, 93: 1246-1256. 10.1093/jnci/93.16.1246.CrossRefPubMed
24.
go back to reference Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA: Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 2006, 66: 867-874. 10.1158/0008-5472.CAN-05-2753.CrossRefPubMed Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA: Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 2006, 66: 867-874. 10.1158/0008-5472.CAN-05-2753.CrossRefPubMed
25.
go back to reference Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC: Molecular cloning and characterization of a novel gene which is highly expressed in hepatocelluar carcinoma. Oncogene. 2002, 21: 4932-4943. 10.1038/sj.onc.1205652.CrossRefPubMed Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC: Molecular cloning and characterization of a novel gene which is highly expressed in hepatocelluar carcinoma. Oncogene. 2002, 21: 4932-4943. 10.1038/sj.onc.1205652.CrossRefPubMed
26.
go back to reference Duffy MJ: Predictive markers in breast and other cancers: a review. Clin Chem. 2005, 51: 494-503. 10.1373/clinchem.2004.046227.CrossRefPubMed Duffy MJ: Predictive markers in breast and other cancers: a review. Clin Chem. 2005, 51: 494-503. 10.1373/clinchem.2004.046227.CrossRefPubMed
Metadata
Title
Differential expression of p42.3 in low- and high-grade gliomas
Authors
Weiqing Wan
Xiaoqing Xu
Guijun Jia
Wenmei Li
Junmei Wang
Tong Ren
Zhen Wu
Junting Zhang
Liwei Zhang
Youyong Lu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-185

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue